SANOFI PASTEUR
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sanofipasteur.com
Study of Inactivated, Split-Virion Influenza Vaccine Compared With the Reference Vaccine Vaxigrip® in the Elderly
Phase 3
Completed
- Conditions
- Orthomyxoviridae InfectionInfluenzaMyxovirus Infection
- Interventions
- Biological: Inactivated, split-virion influenza vaccine
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 3707
- Registration Number
- NCT00383526
Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in Adults
Phase 3
Completed
- Conditions
- InfluenzaMyxovirus InfectionOrthomyxoviridae Infection
- Interventions
- Biological: Inactivated Split-virion influenza vaccine
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 2256
- Registration Number
- NCT00383539
Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV
Phase 3
Completed
- Conditions
- Hepatitis BPolioDiphtheriaPertussisHaemophilus Influenzae Type b
- Interventions
- Biological: DTaP-IPV-HB-PRP~TBiological: CombAct-HIB®Biological: Engerix B® Pediatric
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2014-05-02
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 622
- Registration Number
- NCT00362336
Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®
Phase 2
Completed
- Conditions
- DiphtheriaPertussisPolioHepatitis BTetanus
- Interventions
- Biological: Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 460
- Registration Number
- NCT00362427
Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®
Phase 3
Completed
- Conditions
- HealthyInfant
- Interventions
- Biological: DT3aP-HBs-IPVBiological: DT5aP-IPV-Hib 5-component Pertussis vaccine
- First Posted Date
- 2006-07-24
- Last Posted Date
- 2015-01-07
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 847
- Registration Number
- NCT00355654
Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants
Phase 3
Completed
- Conditions
- DiphtheriaTetanusPertussisHepatitis BInfluenza
- Interventions
- Biological: DTaP-HB-PRP~T combined vaccineBiological: Tritanrix-HepB/Hib™ vaccineBiological: Oral poliomyelitis vaccine (OPV)
- First Posted Date
- 2006-07-06
- Last Posted Date
- 2013-10-22
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 2133
- Registration Number
- NCT00348881
- Locations
- 🇵🇭
Filinvest, Corporate City, Philippines
Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV
Phase 3
Completed
- Conditions
- PoliomyelitisPolio
- Interventions
- Biological: Poliomyelitis Vaccine inactivatedBiological: Poliomyelitis Vaccine in Dragee Candy (Human Diploid Cell)
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 600
- Registration Number
- NCT00348387
Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine
Phase 4
Completed
- Conditions
- PertussisTetanusDiphtheria
- Interventions
- Biological: Tetanus-diphtheria-acellular pertussis (Tdap) vaccine
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 545
- Registration Number
- NCT00347958
A Study of the Immunogenicity and Safety of the 2006-2007 Influenza Vaccine
Phase 2
Completed
- Conditions
- InfluenzaOrthomyxoviridae Infections
- Interventions
- Biological: Inactivated influenza vaccine (split virion)
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2014-01-17
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 120
- Registration Number
- NCT00343681
Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers
Phase 3
Completed
- Conditions
- TetanusHaemophilus Influenzae Type bPoliomyelitisDiphtheriaPertussis
- Interventions
- Biological: PEDIACEL® and Prevenar®Biological: Infanrix®-IPV+Hib and Prevenar®
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 588
- Registration Number
- NCT00343421
© Copyright 2025. All Rights Reserved by MedPath